1. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely <br/ >2. Subjects with infection requiring oxygen support, invasive or non-invasive ventilator support, extracorporeal membrane oxygenation (ECMO) or shock requiring vasopressor support. <br/ >3. Current known pneumonia based on x-ray or computed tomography (CT) scan or history of pneumonia within 3 months before screening. <br/ >4. Requiring hospitalization for the treatment of COVID-19 <br/ >5. Prolonged QT, defined as QTcF â?¥ 450 milliseconds for men and as QTcF â?¥ 470 milliseconds for women <br/ >6. Requires ICU care for management of ongoing clinical status. <br/ >7. Known allergy or hypersensitivity to Nitric Oxide Nasal Spray. <br/ >8. Asthma, allergic rhinitis or chronic obstructive lung disease <br/ >9. Pregnant or lactating women, <br/ >10. Having used Nitric Oxide Nasal Spray or participated in any other interventional drug clinical study within 30 days prior to first dose of study drug.

1. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely <br/ >2. Subjects with infection requiring oxygen support, invasive or non-invasive ventilator support, extracorporeal membrane oxygenation (ECMO) or shock requiring vasopressor support. <br/ >3. Current known pneumonia based on x-ray or computed tomography (CT) scan or history of pneumonia within 3 months before screening. <br/ >4. Requiring hospitalization for the treatment of COVID-19 <br/ >5. Prolonged QT, defined as QTcF â?¥ 450 milliseconds for men and as QTcF â?¥ 470 milliseconds for women <br/ >6. Requires ICU care for management of ongoing clinical status. <br/ >7. Known allergy or hypersensitivity to Nitric Oxide Nasal Spray. <br/ >8. Asthma, allergic rhinitis or chronic obstructive lung disease <br/ >9. Pregnant or lactating women, <br/ >10. Having used Nitric Oxide Nasal Spray or participated in any other interventional drug clinical study within 30 days prior to first dose of study drug.

N/A

N/A

1. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely <br/ >2. Subjects with infection requiring oxygen support, invasive or non-invasive ventilator support, extracorporeal membrane oxygenation (ECMO) or shock requiring vasopressor support. <br/ >3. Current known pneumonia based on x-ray or computed tomography (CT) scan or history of pneumonia within 3 months before screening. <br/ >4. Requiring hospitalization for the treatment of COVID-19 <br/ >5. Prolonged QT, defined as QTcF â?¥ 450 milliseconds for men and as QTcF â?¥ 470 milliseconds for women <br/ >6. Requires ICU care for management of ongoing clinical status. <br/ >7. Known allergy or hypersensitivity to Nitric Oxide Nasal Spray. <br/ >8. Asthma, allergic rhinitis or chronic obstructive lung disease <br/ >9. Pregnant or lactating women, <br/ >10. Having used Nitric Oxide Nasal Spray or participated in any other interventional drug clinical study within 30 days prior to first dose of study drug.

1. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely <br/ >2. Subjects with infection requiring oxygen support, invasive or non-invasive ventilator support, extracorporeal membrane oxygenation (ECMO) or shock requiring vasopressor support. <br/ >3. Current known pneumonia based on x-ray or computed tomography (CT) scan or history of pneumonia within 3 months before screening. <br/ >4. Requiring hospitalization for the treatment of COVID-19 <br/ >5. Prolonged QT, defined as QTcF â?¥ 450 milliseconds for men and as QTcF â?¥ 470 milliseconds for women <br/ >6. Requires ICU care for management of ongoing clinical status. <br/ >7. Known allergy or hypersensitivity to Nitric Oxide Nasal Spray. <br/ >8. Asthma, allergic rhinitis or chronic obstructive lung disease <br/ >9. Pregnant or lactating women, <br/ >10. Having used Nitric Oxide Nasal Spray or participated in any other interventional drug clinical study within 30 days prior to first dose of study drug.